top button
    Got Questions


Global IoT Summit 2018
Oct 31, 2018
The Leela Palace, Bangalore



    Connect to us
      Facebook Login
      Site Registration Why to Join

Facebook Login
Site Registration

Neuromuscular Blocking Agents Market Key Insights, Profiling Companies and Growth Strategies

0 votes
6 views

The neuromuscular blocking agent is also known as a paralyzing agent as they block the connection between nerves and muscles and paralyzed muscle function of the body. Neuromuscular blocking agents are potent muscle relaxant which is particularly used during surgery to prevent muscle movement and for mechanical ventilation. Neuromuscular blocking agents normally work as a pre-junctional receptor and post junctional receptor. Neuromuscular blocking agents are indicated for a wide variety of uses in hospital settings, from surgeries to trauma.

Report Overview @ https://www.transparencymarketresearch.com/neuromuscular-blocking-agents-market.html

Neuromuscular blocking agent is used as an adjuvant in general anesthesia, electroshock therapy, endotracheal intubation, during incubation and endoscopic procedures, brief surgeries and as adjuncts in the treatment of encephalitis, tetanus, and poliomyelitis which propels the demand of the neuromuscular blocking agents over the forecast period.

The global neuromuscular blocking agent market is segmented on the basis of drug class, drug group, and distribution channel.

  • On the basis of drug class, the global neuromuscular blocking agent market is segmented into:
    • Pachycurares
    • Leptocurares
  • On the basis of drug group, the global neuromuscular blocking agent market is segmented into:
    • Non-polarizing agents (Competitive)
    • Depolarizing agents (Non-competitive) 
  • On the basis of distribution channel, the global neuromuscular blocking agent market is segmented into:
    • Hospital Pharmacy
    • Retail Pharmacy
    • Drug stores
    • E- Commerce

Request PDF Sample of Neuromuscular Blocking Agents Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=25961

The global neuromuscular blocking agent market is anticipated to register a significant CAGR over a forecast period. The increasing use of the neuromuscular blocking agent in the surgeries is anticipated to boost the demand of the neuromuscular blocking agent and drives the global neuromuscular blocking agent market.

The rising geriatric population is also expected to propel the demand of the neuromuscular blocking agent and drives the global neuromuscular blocking agent market. The increasing research and development activities for the new drugs and new combinations of drugs to minimize the side effects of the blocking agents and increase safety and efficacy of the drug, also anticipated to drives the global neuromuscular blocking agent market.

However, the possible side effects of the neuromuscular blocking agent such as hyperkalemia, dysrhythmia, cardiac arrest, muscle pain and prolonged paralysis, which may hamper the demand for the neuromuscular blocking agent and restrain the growth of the global neuromuscular blocking agent market. The possibilities of injuries and death due to the substitution errors involved in these drugs may also hamper the demand of the neuromuscular blocking agent and restraint the growth of the global neuromuscular blocking agent market.

On the basis of regional presence, the global neuromuscular blocking agent market is segmented into seven key regions: North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan, Japan, and Middle East & Africa. Currently, North America is contributing the leading shares to the global neuromuscular blocking agent market in terms of value and anticipated to register a significant CAGR over a forecast period. The Europe is also contributing the moderate shares to the market due to the increasing use of the neuromuscular blocking agent during surgeries.

Pre Book “Neuromuscular Blocking Agents Market” Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=25961&ltype=S

APAC is the most lucrative market for the neuromuscular blocking agent due to the increasing use of drugs during the surgical procedures in the region and expected to show a robust growth to the global neuromuscular blocking agent market. MEA is at a nascent stage to the global neuromuscular blocking agent market and anticipated to register a decent growth to the market over a forecast period. Overall, the global neuromuscular blocking agent market is expected to show significant growth over a forecast period.

Some of the major market players in neuromuscular blocking agent market globally include Aqua Pharmaceuticals, Merck & Co., Inc., Hikma Pharmaceuticals PLC., GlaxoSmithKline Plc., Abbott Laboratories, AbbVie Inc., Pfizer, Novartis AG, Bayer AG, Roche Inc. and Zydus Cadila.

More Trending Reports by Transparency Market Research –

Non-invasive Prenatal Testing Market: prnewswire.com/news-releases/non-invasive-prenatal-testing-market-to-cross-us-5-000-million-by-2027—says-tmr-300865294.html

Global Wound Healing Market: prnewswire.com/news-releases/global-wound-healing-market-to-reach-over-us-350-billion-by-2025-says-tmr-676809663.html

posted Feb 11 by Bella Watson

  Promote This Article
Facebook Share Button Twitter Share Button Google+ Share Button LinkedIn Share Button Multiple Social Share Button

Related Articles
0 votes

According to the report by Transparency Market Research (TMR), the global interventional cardiology devices market has highly consolidated landscape. Some of the key players operating in the global interventional cardiology devices market are Boston Scientific, Medtronic, Abbott Vascular, St Jude Medical, and Volcano Corporation. Among these, the three players including Boston Scientific, Medtronic, and Abbott Vascular are accounting for the share of 66.9%.

According to a report by Transparency Market Research (TMR), the global interventional cardiology devices market is expected to expand with a CAGR of 2.9% from 2014 to 2022, to attain the value of US$11.16 bn by the end of 2022 from US$9.36 bn in the year 2016. On the basis of product type, the stents segment is dominating the global market for interventional cardiology devices and expected to continue its dominance over the forecast period by collecting revenue of about US$6.89 bn until the end of 2022. On the basis of region, North America is dominating the global market for interventional cardiology devices and expected to continue its dominance by collecting US$4.04 bn by the end of 2022. This growth is attributable to the high adoption of the stents.

Get Sample with Latest Research @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=853

Technological Advancements to Fuel Adoption  

Increasing geriatric population and obesity are leading to an increase in the prevalence of cardiovascular disease. Additionally, changing lifestyle that is characterized by smoking, high alcohol consumption, and lack of physical exercise have increased the prevalence of coronary artery diseases. The interventional cardiology devices help cardiologists to perform the procedures quickly, without letting the procedure to get complicated. Rising demand for the safe and advanced technology is fuelling growth of the global interventional cardiology devices market.

The treatment of cardiovascular disorders has changed from past few years owing to introduction of new drugs and advanced therapies which helps to live better and longer lives. Advancement in research and development (R&Ds) activities to develop novel drugs and devices plays a key role in the growth of the market. The continuous technological advancement in the interventional cardiology devices market is boosting adoption which is likely to fuel growth of the global interventional cardiology devices market.  

Buy Now Interventional Cardiology Devices Market Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=853&ltype=S

Government Initiatives for Improving Knowledge to Create Opportunities

Despite these growth opportunities, high manufacturing cost of these devices is a major factor hampering growth of the global interventional cardiology devices market. Additionally, price cut by the local players is pressurizing global players to reduce their prices which is crimping growth of the global interventional cardiology devices market. Nevertheless, numerous initiatives by the governments to increase awareness level about cardiovascular diseases and importance of regular medical checkup camps are creating lucrative opportunities for the growth of market.

More Trending Reports by Transparency Market Research –

Helicobacter Pylori (H. Pylori) Non-invasive Testing Market: prnewswire.com/news-releases/helicobacter-pylori-h-pylori-non-invasive-testing-market-to-be-worth-us-700-mn-by-2026-says-tmr-685104651.html

Brain Computer Interface Market: prnewswire.com/news-releases/brain-computer-interface-market-to-be-worth-us-12-billion-by-2024-demand-increases-with-growing-prevalence-of-brain-disorders—tmr-682767451.html

0 votes

The demand within the global market for rehabilitation products and services has been rising on account of advancements in the domain of home healthcare, finds Transparency Market Research (TMR). The global market for home rehabilitation products and services displays a fairly consolidated competitive landscape, majorly due to the strongholds of a handful of market vendors. Furthermore, the leading market players have made concerted efforts to ensure that they reap continual revenues in order to maintain their position. It is projected that these market vendors would bank effective distribution channels to further expand their consumer base and fetch larger revenues. In order to eliminate possible competition, the leading vendors are projected to acquire emerging players in the global market for home rehabilitation products and services market.

The market players have introduced all-time availability of products as the most recent policy in their quest for expanding their market share. Moreover, collaborative agreements are another key strategy that has outshone all other strategies meant to benefit the market vendors. Besides this, mergers, strategic alliances, and partnerships are also projected to be the key highlights of the global market for rehabilitation products and services.

Transparency Marker Research (TMR) predicts that the global market for home rehabilitation products and services market is projected to expand at a healthy CAGR of 8.3% over the period between 2018 and 2026. Furthermore, the global home rehabilitation products and services market is expected to touch a value of US$ 161,743.4 Mn by 2026 from a value of US$ 88,484.0 Mn in 2017.

Request PDF Sample of Home Rehabilitation Products and Services Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=6053

Increasing Cases of Physical Handicap to Propel Market Demand

The most important concern of the healthcare industry is to provide proper treatment and care to all population demographics. However, a large population of people are barred of the ability to visit doctors or hospitals due to their physical handicaps. Owing to this factor, the demand within the global market for homer rehabilitation products and services has been rising at a robust rate over the past decade.

Furthermore, the urban population has become increasingly reliant on healthcare services provided at home, thus, enhancing the growth prospects of the global market for home rehabilitation products and services. The incidence of chronic diseases such as diabetes, cardiovascular disorders, and cancers has risen at unprecedented scale over the past decade. This has also created commendable growth opportunities within the global market for home rehabilitation products and services.

Enquiry for Discount on “Home Rehabilitation Products and Services Market” Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=6053

High Costs Home Rehabilitation Services to Hamper Growth

Home rehabilitation services, in most cases, necessitate the presence of a medical expert or attendant to look after the patient throughout the day. Furthermore, special aids and equipments also need to be installed to meet the needs and requirements of the patient. All of this takes the cumulative expenses on home rehabilitation to unaffordable levels for a lot of people. Owing to this reason, the market is expected to suffer several roadblocks before attaining fruition on a global scale. Moreover, the lack of proper medical reimbursements and unavailability of medical staff also restrains the growth of the global market for home rehabilitation products and services.

More Trending Reports by Transparency Market Research –

Non-invasive Prenatal Testing Market: prnewswire.com/news-releases/non-invasive-prenatal-testing-market-to-cross-us-5-000-million-by-2027—says-tmr-300865294.html

Global Wound Healing Market: prnewswire.com/news-releases/global-wound-healing-market-to-reach-over-us-350-billion-by-2025-says-tmr-676809663.html

0 votes

Transparency Market Research (TMR) has published a new report titled, “Depression Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global depression drugs market was valued at US$ 6,500 Mn in 2017 and is anticipated to decline at a CAGR of 2% from 2018 to 2026. The report suggests that rise in incidence of major depression disorders is projected to drive demand for depression drugs from 2018 to 2026. Key players introduce their new depression drugs in developed regions such as Western Europe and North America. Hence, these regions are likely to account for significant share of the global depression drugs market. Rise in burden of schizophrenia and bipolar I disorder in emerging markets such as China and India is likely to boost the growth of the market in Asia Pacific during the forecast period.

Loss of Patents to Restrain Global Market

Depression is an indication where a patient feels down in the dumps, miserable, unhappy, blue, or sad. For short period of time, many people may feel this way at a time or another. True clinical depression is when a patient feels frustrated, angry, lost, and sad on a daily basis for a long period of time. Increase in prevalence of major depression disorders is projected to drive the market during the forecast period. According to the National Institute of Mental Health (NIMH), the U.S. adult population of approximately 10.3 million had at least one major depressive disorder episode with huge impairment. The population accounts for 4.3% of all adults in the country. Higher prevalence was observed among female adults at 8.5% as compared to 4.8% among male adults. The highest prevalence of major depression disorder episode was observed among people aged 18 to 25 at 10.9%.

Request PDF Sample of Depression Drug Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1151

Atypical Antipsychotics to Lose Market Share

The global depression drugs market has been segmented based on drug class, disease type, distribution channel, and region. In terms of drug class, the market has been categorized into atypical antipsychotics, serotonin-norepinephrine reuptake inhibitor, selective serotonin reuptake inhibitor, central nervous system (CNS) stimulant, and others. The atypical antipsychotics segment leads the market and is expected to continue its dominance during the forecast period, followed by serotonin-norepinephrine reuptake inhibitor. High market share of the atypical antipsychotics segment is attributed to the launch of drugs in developed countries such as the U.S. and Canada. Based on disease type, the global depression drugs market has been classified into major depressive disorders, schizophrenia and bipolar I disorder, selective serotonin reuptake inhibitor induced, and others.

Online Pharmacies to Gain Market Share

Based on distribution channel, the global depression drugs market has been segmented into online pharmacies, hospital pharmacies, and retail pharmacies. The retail pharmacies segment held significant market share in 2017, and is anticipated to dominate the market during the forecast period. This large market share is attributed to rise in prevalence of major depression disorders across the world and increase in preference of depressed patients to purchase from retail pharmacies. However, the hospital pharmacies and retail pharmacies segments are anticipated to lose market share during the forecast period owing to exclusivity expiry of depression drugs.

Enquiry for Discount on “Depression Drug Market ” Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=1151

Middle East & Africa to Offer Significant Incremental Opportunity and Register High Growth

North America captured large share of the global depression drugs market in 2017. The region is home to several key players in the global depression drugs market. Hence, the region is likely to dominate the global market during the forecast period. Europe held the second largest share of the global depression drugs market in 2017. Increase in research and development on depression drugs is attributed to high market share of the region. The market in Middle East & Africa is anticipated to expand at the fastest growth rate during the forecast period. Increase in government initiatives in health care sector is projected to fuel the growth of the market in the region. Initiatives by local governments to attain self-sufficiency in manufacturing depression drugs is likely to boost market growth in Asia Pacific and Latin America.

Companies such as Otsuka Pharmaceutical Co., Ltd. and Eli Lilly and Company to Lead the Market

Key players operating in the global depression drugs market and profiled in the report include Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Company, Pfizer, Inc., AstraZeneca, Allergan USA, Inc., Novartis AG, GlaxoSmithKline, Takeda Pharmaceutical Company Ltd, Sebela Pharmaceutical, Inc., and Johnson & Johnson. These players adopt inorganic and organic growth strategies to increase drug offerings, strengthen reach across the world, garner market share, and increase customer base.

0 votes

Transparency Market Research (TMR) has published a new report titled, “Depression Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global depression drugs market was valued at US$ 6,500 Mn in 2017 and is anticipated to decline at a CAGR of 2% from 2018 to 2026. The report suggests that rise in incidence of major depression disorders is projected to drive demand for depression drugs from 2018 to 2026. Key players introduce their new depression drugs in developed regions such as Western Europe and North America. Hence, these regions are likely to account for significant share of the global depression drugs market. Rise in burden of schizophrenia and bipolar I disorder in emerging markets such as China and India is likely to boost the growth of the market in Asia Pacific during the forecast period.

Loss of Patents to Restrain Global Market

Depression is an indication where a patient feels down in the dumps, miserable, unhappy, blue, or sad. For short period of time, many people may feel this way at a time or another. True clinical depression is when a patient feels frustrated, angry, lost, and sad on a daily basis for a long period of time. Increase in prevalence of major depression disorders is projected to drive the market during the forecast period. According to the National Institute of Mental Health (NIMH), the U.S. adult population of approximately 10.3 million had at least one major depressive disorder episode with huge impairment. The population accounts for 4.3% of all adults in the country. Higher prevalence was observed among female adults at 8.5% as compared to 4.8% among male adults. The highest prevalence of major depression disorder episode was observed among people aged 18 to 25 at 10.9%.

Request PDF Sample of Depression Drug Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1151

Atypical Antipsychotics to Lose Market Share

The global depression drugs market has been segmented based on drug class, disease type, distribution channel, and region. In terms of drug class, the market has been categorized into atypical antipsychotics, serotonin-norepinephrine reuptake inhibitor, selective serotonin reuptake inhibitor, central nervous system (CNS) stimulant, and others. The atypical antipsychotics segment leads the market and is expected to continue its dominance during the forecast period, followed by serotonin-norepinephrine reuptake inhibitor. High market share of the atypical antipsychotics segment is attributed to the launch of drugs in developed countries such as the U.S. and Canada. Based on disease type, the global depression drugs market has been classified into major depressive disorders, schizophrenia and bipolar I disorder, selective serotonin reuptake inhibitor induced, and others.

Online Pharmacies to Gain Market Share

Based on distribution channel, the global depression drugs market has been segmented into online pharmacies, hospital pharmacies, and retail pharmacies. The retail pharmacies segment held significant market share in 2017, and is anticipated to dominate the market during the forecast period. This large market share is attributed to rise in prevalence of major depression disorders across the world and increase in preference of depressed patients to purchase from retail pharmacies. However, the hospital pharmacies and retail pharmacies segments are anticipated to lose market share during the forecast period owing to exclusivity expiry of depression drugs.

Enquiry for Discount on “Depression Drug Market ” Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=1151

Middle East & Africa to Offer Significant Incremental Opportunity and Register High Growth

North America captured large share of the global depression drugs market in 2017. The region is home to several key players in the global depression drugs market. Hence, the region is likely to dominate the global market during the forecast period. Europe held the second largest share of the global depression drugs market in 2017. Increase in research and development on depression drugs is attributed to high market share of the region. The market in Middle East & Africa is anticipated to expand at the fastest growth rate during the forecast period. Increase in government initiatives in health care sector is projected to fuel the growth of the market in the region. Initiatives by local governments to attain self-sufficiency in manufacturing depression drugs is likely to boost market growth in Asia Pacific and Latin America.

Companies such as Otsuka Pharmaceutical Co., Ltd. and Eli Lilly and Company to Lead the Market

Key players operating in the global depression drugs market and profiled in the report include Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Company, Pfizer, Inc., AstraZeneca, Allergan USA, Inc., Novartis AG, GlaxoSmithKline, Takeda Pharmaceutical Company Ltd, Sebela Pharmaceutical, Inc., and Johnson & Johnson. These players adopt inorganic and organic growth strategies to increase drug offerings, strengthen reach across the world, garner market share, and increase customer base.

0 votes

In Vitro Toxicology Testing Market: Introduction

  • Toxicology or toxicity, also known as ‘the science of poisons,’ is a method of testing the opposing effects of any drug, chemical or other agent administered in the body. It, thus, analyses the adverse effects of various toxins on all living organisms.
  • In vitro toxicology testing does not make use of whole animals or whole organisms. It rather uses tissue slices, isolated organs, cell lines isolated primary cell cultures, explants cultures, and subcellular fractions such that of mitochondria and membranes.
  • In vitro toxicology testing also helps in determining the drug safety profile at an early stage, thus saving a considerable amount of time and resource investment

Report Overview @ https://www.transparencymarketresearch.com/in-vitro-toxicology-testing-market.html

To understand how our report can bring difference to your business strategy, Ask for a brochure

Key Drivers and Restraints of Global In Vitro Toxicology Testing Market

  • Scientific concerns over animal experiments have been raised in the field of toxicology testing. It entails problems such as difference between various test animals and resultant effects of toxicants, characterization of actions of these toxins on different animals, and categorization of test animals on the basis of their biology and effects of toxins.
  • Animal testing has been in effect since long; however, the implementation of in vitro toxicology testing is an alternative to animal testing. It is effective and harmless as compared to animal testing.
  • In vitro toxicology is cost effective and growing ethical concerns worldwide are expected to drive the in vitro toxicology market during the forecast period. Pharmaceutical companies are, thus, increasingly shifting their focus from animal testing to in vitro toxicology testing.

To Know the Scope of Our Report Get a Brochure on “In Vitro Toxicology Testing Market” here @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=73510

  • Advantages of in vitro toxicology testing over traditional methods of animal testing in terms of quick turnaround time and better sample control will also help the global market to grow at a rapid rate
  • Opposition to animal testing will have a major impact on the in vitro toxicology testing market, as animal testing will be reduced to a large extent

Cellular Assay Technology Segment to Lead Global In Vitro Toxicology Testing Market

  • In terms of technology, the global in vitro toxicology testing market can be divided into cellular assay, biochemical assay, in silica, and ex-vivo
  • In the present scenario, cellular assay methods are widely used by industries in safety assessment, risk evaluation, and toxicity testing. The cellular assay method is mainly used to elucidate mechanisms of toxicity in a drug and its effect on a cell or a tissue.

Pharmaceutical Industry Segment to Offer Growth Opportunities

  • Based on end-user, the global in vitro toxicology testing market can be categorized into cosmetics & household products, pharmaceutical industry, food industry, and chemicals industry
  • Pharmaceutical industry is estimated to be a highly lucrative segment. Pharmaceuticals play a major role in in vitro toxicology testing, as the test is to identify the toxicity of various chemical drugs and their effects on the human body. Chemicals are used in various products, which has a direct or indirect effect on the human body .Thus, in vitro toxicology can be useful in finding the toxic nature of such chemicals and their effects on the human body.

Pre Book “In Vitro Toxicology Testing Market” Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=73510&ltype=S

North America to Lead Global In Vitro Toxicology Testing Market

  • The global in vitro toxicology testing market can be divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is a significant market for in vitro toxicology testing due to the presence of several key market players.
  • Substantial investments in research and development by various end-user segments in the region are anticipated to drive the global in vitro toxicology testing market in North America

Key Players Operating in Global In Vitro Toxicology Testing Market

Key players operating in the global in vitro toxicology testing market are:

  • Abbott Laboratories
  • Bio-Rad Laboratories, Inc.
  • Agilent Technologies, Inc.
  • Cyprotex
  • Charles River Laboratories, Inc.
  • Covance, Inc.
  • Thermo Fisher Scientific, Inc.
...